There was no mention on production volumes. 2 or 5 cent royalty...

There was no mention on production volumes.
2 or 5 cent royalty is zero if they are not produced as we see with other UNIS syringe contracts.
Nothing is as easy as it seems- but ways that BD could hamper any syringe sales by UNIS is just to discount their own products.
There is another potential problem for syringes listed in the risk disclosures and that is that some components maybe/ are supplied by competitors and their supply could be disrupted.
Wearables should not suffer the same problem as they are a new market and not disrupting anyone's business.
I just find it hard to understand that BD has stood back and done nothing to prevent UNIS establishing itself in the syringe business.
The next few weeks and months are going to be exciting, provided UNIS doesn't go under- which I feel that they won't.
All IMO